Yesterday, the Boeing Company (BA) announced that its board had authorized the purchase of as much as $7 billion in common stock or close to 10% of all the outstanding shares. This follows a $3 billion repurchase that begun in August last year and is nearing completion. This announcement comes right after the company reported a solid earnings last Wednesday. Boeing reported its third-quarter earnings were up almost 60 percent to $1.1 billion and revenues of $16.52 billion, beating Wall Street expectations. However, the company took a conservative stance with its outlook because of delays with the 787 Dreamliner and growth slowing at its defense unit. Boeing likes the value it sees in its stock and has been an aggressive buyer of it, buying back close to $8 billion since 2004. The Chicago-based company’s chief executive, Jim McNerney, said in a statement, “Our strong financial performance allows us to return value to our shareholders while continuing to invest in our growth and becoming more productive.” McNerney added, “We are executing a balanced cash deployment strategy that's serving Boeing and its shareholders well.”

Director, Paul Fribourg, continues buying up shares.

PACCAR announced its Board approved the buyback of $300 million of its stock. PACCAR has invested $978 million to repurchase 27.4 million shares. PACCAR Inc has two principal industry segments: design, manufacture and distribution of light, medium and heavy-duty trucks, and related aftermarket distribution of parts (Trucks), and finance and leasing services provided to customers and dealers (Financial Services).

American Physicians Capital announced that the Board authorized the repurchase of an additional $20 million of its common shares in 2008.

QLT Inc. CEO, Robert L. Butchofsky, disclosed a purchase of 39,847 shares at prices from $4.40-$4.65, bringing his stake to 74,847 shares. QLT Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies.